Carnosine / angioG Cancer Research Results

Carno, Carnosine: Click to Expand ⟱
Features:

Carnosine (CAR; β-alanyl-L-histidine) is an endogenous dipeptide and dietary supplement (high in meat; also synthesized).
Primary mechanisms (conceptual rank):
1) Carbonyl/aldehyde scavenging + anti-glycation (AGE) suppression → proteostasis stress ↓ (P/R)
2) Cancer metabolism interference (Warburg/glycolysis pressure) → proliferation ↓ (model-dependent; often high concentration) (R/G)
3) Metal chelation + ROS/RNS buffering (secondary redox modulation) (P/R; context-dependent)
Bioavailability / PK: Orally absorbed, but rapidly hydrolyzed in human blood by carnosinase (CN1) → very short circulating half-life; sustained systemic CAR exposure is limited vs β-alanine/histidine metabolites.
In-vitro vs realistic exposure: Many anti-proliferative / glycolysis effects are reported at high µM–mM CAR in vitro, commonly exceeding realistic systemic CAR exposure due to rapid serum hydrolysis.
Clinical evidence status (cancer): Predominantly preclinical for direct anti-cancer effects; human oncology evidence is mainly adjunct/supportive (e.g., zinc-L-carnosine for radiation-related symptoms), not established as an anti-tumor monotherapy.

L-Carnosine (usually just called "Carnosine") is a naturally occurring dipeptide composed of L-histidine and β-alanine, found in high concentrations in muscle and brain tissue.
-Source: only found in animals Beef(372mg/100g), ChickenBreast(290mg/100g), Pork(276mg/100g), TurkeyBreast(240mg/100g)
-Anserine is a derivative of carnosine
-Scavenges reactive oxygen species (ROS)
-Inhibits formation of AGEs (advanced glycation end-products), which are linked to aging and neurodegeneration.
-Metal chelator: Binds excess zinc, copper, and iron—important in brain health.


Carnosine (CAR) — Pathway / Axis Effects (Cancer vs Normal)

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Carbonyl stress / anti-glycation (AGE) ↓ proteotoxic/carbonyl stress (context-dependent) ↓ glycation damage (protective) P/R Cell stress buffering Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation.
2 Warburg / glycolysis pressure ↓ glycolysis flux (model-dependent; high concentration only) ↔ R/G Anti-proliferative (subset) Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans.
3 Mitochondrial function / energetic stress ↔ / ↑ energetic stress (model-dependent) ↔ / protective (context-dependent) R Growth suppression vs resilience Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects.
4 ROS ↓ ROS (secondary; context-dependent) ↓ oxidative damage (protective) P/R Redox buffering Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative.
5 NRF2 (stress-response axis) ↔ / ↑ cytoprotection (context-dependent; resistance risk) ↔ / ↑ protective G Adaptive stress signaling If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable.
6 Ca²⁺ (ER/mitochondria stress coupling) ↔ (not primary; model-dependent) ↔ R Stress modulation (secondary) Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control.
7 Ferroptosis ↔ (context-dependent) ↔ R/G Unclear / secondary CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry.
8 Clinical Translation Constraint Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. — PK-limited; adjunct-only Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology.

TSF legend: P: 0–30 min (primary/rapid effects; direct enzyme/redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
angioG, angiogenesis: Click to Expand ⟱
Source:
Type:
Process through which new blood vessels.
Angiogenesis, the process of new blood vessel formation from pre-existing vessels, plays a crucial role in cancer progression and metastasis. Tumors require a blood supply to grow beyond a certain size and to spread to other parts of the body.
Vascular Endothelial Growth Factor (VEGF): VEGF is one of the most important pro-angiogenic factors. It stimulates endothelial cell proliferation and migration, leading to the formation of new blood vessels. Many tumors overexpress VEGF, which correlates with poor prognosis.
Hypoxia-Inducible Factor (HIF): In response to low oxygen levels (hypoxia), tumors can activate HIF, which in turn promotes the expression of VEGF and other angiogenic factors. This mechanism allows tumors to adapt to their microenvironment and sustain growth.
Scientific Papers found: Click to Expand⟱
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
*ROS↓, *IronCh↑, *AntiAge↑, *antiOx↑, *Inflam↓, *neuroP↑, *lipid-P↓, *toxicity↓, *NOX4↓, *SOD↑, *HNE↓, *IL6↓, *TNF-α↓, *IL1β↓, *Sepsis↓, *eff↑, *GABA↝, *Aβ↓, Glycolysis↓, AntiTum↑, p‑Akt↓, TumCCA↑, angioG↓, VEGFR2↓, NF-kB↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HNE↓, 1,   lipid-P↓, 1,   NOX4↓, 1,   ROS↓, 1,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

GABA↝, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: angioG, angiogenesis
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:351  Target#:447  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page